yahoo_financeOriginal article
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
Phase 2positivePGN-EDODM1Positive
AI Analysis
Summary
PepGen announced that the Data Safety Monitoring Board approved advancement of PGN-EDODM1 to the highest dose cohort in the Phase 2 FREEDOM2-DM1 study for Duchenne muscular dystrophy treatment.
Clinical Trial Data
Phase
2
Outcome Details
Data Safety Monitoring Board review supported advancement to highest dose cohort
Importance:6/10
Sentiment:
0.65
Phase 2DSMB reviewdose escalationDuchenne muscular dystrophyclinical development
Related Companies
Read the original article
Published by yahoo_finance on August 6, 2026 11:30 AM